Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation.
Girnius
S
S
Seldin
D C
DC
Quillen
K
K
Dember
L M
LM
Segal
A
A
Sanchorawala
V
V
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000378:metabolism*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010265:Paraproteinemias / Q000188:drug therapy* / Q000378:metabolism / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D014182:Transplantation, Autologous / Q000009:adverse effects; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D019653:Myeloablative Agonists; D008558:Melphalan
Nephrol Dial Transplant. 2008 Jun;23(6):2052-7
18178602
Ann Intern Med. 2004 Jan 20;140(2):85-93
14734330
Kidney Int. 2004 Feb;65(2):642-8
14717936
Clin J Am Soc Nephrol. 2007 Jul;2(4):858-67
17699503
Haematologica. 2009 Feb;94(2):300-2
19066331
Am J Kidney Dis. 2003 Dec;42(6):1154-63
14655186
Bone Marrow Transplant. 2006 Sep;38(5):339-43
16862166
Bone Marrow Transplant. 2008 Sep;42(6):405-12
18574442